Pharmaceutical - Vivus

Filter

Current filters:

Vivus

Popular Filters

1 to 25 of 39 results

FDA at last approves weight-management drug Contrave

FDA at last approves weight-management drug Contrave

11-09-2014

After considerable delay, the US Food and Drug Administration late yesterday finally granted approval…

Arena PharmaceuticalsBelviqContraveMetabolicsOrexigen TherapeuticsPharmaceuticalQnexaRegulationTakeda PharmaceuticalsUSAVivus

Vivus acquires topiramate patents from Janssen

Vivus acquires topiramate patents from Janssen

26-08-2014

USA-based pharma company Vivus has acquired a group of patents from Johnson & Johnson’s Janssen Pharmaceuticals…

AnorecticsEuropean Medicines AgencyJanssen PharmaceuticaLicensingObesityPharmaceuticalPhentermine/topiramateQsymiaTopiramateUSAVivus

Vivus earnings beat expectations

25-02-2014

USA-based Vivus has reported fourth-quarter and full-year 2013 financial results that beat analysts’…

FinancialPharmaceuticalVivus

Auxilium gains rights to Vivus ED drug for USA and Canada

11-10-2013

Auxilium Pharmaceuticals has signed an agreement with fellow USA-based Vivus providing Auxilium with…

Auxilium PharmaceuticalsLicensingMen's HealthNorth AmericaPharmaceuticalStendraVivus

Vivus obesity drug reduces progression to type 2 diabetes in high-risk overweight patients

10-10-2013

New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’…

DiabetesMetabolicsPharmaceuticalQsymiaResearchVivus

Market for obesity therapies to reach a value of $2.6 billion in 2019

16-09-2013

The global obesity therapeutics market has been forecast to increase at a compound annual growth rate…

GlobalMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Anti-obesity drug market to more than triple by 2019; report

05-09-2013

The anti-obesity drug market, which is dominated by off-patent orlistat, Swiss pharma major Roche's (ROG:…

Markets & MarketingMetabolicsorlistatPharmaceuticalQsymiaRocheVivusXenical

Resubmission expected for Orexigen's obesity drug Contrave

29-08-2013

US biopharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that the Light Study independent…

Arena PharmaceuticalsBelviqContraveGastro-intestinalsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

Sanofi to produce avanafil for Vivus

02-08-2013

US drugmaker Vivus (Nasdaq: VVUS) says it has entered into a commercial supply agreement with French…

avanafilMen's HealthPharmaceuticalProductionSanofiSpedraVivus

Vivus reaches agreement with First Manhattan and appoints new board

19-07-2013

A truce has been called between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

ManagementNorth AmericaPharmaceuticalVivus

Law suit threat for Vivus over battle for shareholders' votes

17-07-2013

The battle has heated up between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

FinancialNorth AmericaPharmaceuticalQsymiaVivus

Vivus offers a compromise to end the proxy contest

14-07-2013

US drugmaker Vivus (Nasdaq: VVUS) said on Saturday (July 13) that it had communicated to Sam Colin and…

ManagementPharmaceuticalQsymiaVivus

European approval for Vivus' ED drug Spedra

27-06-2013

The European Commission yesterday (June 26) has granted marketing authorization for USA-based Vivus'…

avanafilEuropeMen's HealthPharmaceuticalRegulationReproductiveSpedraVivus

It's official: "obesity is a disease," says AMA

20-06-2013

The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus rises as FDA eases restrictions on diet pill Qsymia

17-04-2013

USA drugmaker Vivus' (Nasdaq: VVUS) shares rose as much as 11% by traded up 5% at $11.69, after the company…

MetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus announces new discount program for obesity drug Qsymia

06-03-2013

US drugmaker Vivus (Nasdaq: VVUS) has announced a new program offering eligible patients a discount on…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalPricingQsymiaVivus

EMA confirms negative view on Vivus' obesity drug Qsiva after appeal

22-02-2013

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dealt a blow to…

EuropeMetabolicsPharmaceuticalQsivaQsymiaRegulationVivus

Express Scripts adds Vivus' Qsymia to its standard benefits program

20-12-2012

US drugmaker Vivus (Nasdaq: VVUS) says that Express Scripts, among the USA's largest Pharmacy Benefit…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

Vivus gets formal "No" from EMA panel on obesity drug

19-10-2012

US drugmaker Vivus (Nasdaq: VVUS) revealed yesterday that is has received the formal opinion from the…

EuropeMetabolicsPharmaceuticalQsivaRegulationVivus

Strong start for Vivus' obesity drug Qsymia; deal with Express Scripts

10-10-2012

Sales of US drugmaker Vivus' (Nasdaq: VVUS) obesity agent Qsymia (phentermine and topiramate extended-release)…

Express ScriptsMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaVivus

1 to 25 of 39 results

Back to top